Aim: Fast-progressing vascular calcification (VC) is accompanied by renal atrophy and functional deterioration along with atherosclerosis in patients with chronic kidney disease (CKD). However, the relationship between VC progression and renal functional and/or morphological changes remains unclear. Methods: We included 70 asymptomatic patients with CKD without hemodialysis in our study. To identify temporal variations, the coronary artery calcification score (CACS), abdominal aortic calcification index (ACI), and renal parenchymal volume index (RPVI) were determined via spiral computed tomography scans taken during the study. We investigated significant factors related to annualized variations of CACS ( CACS/y) and ACI ( ACI/y). 
abnormalities, nutrition status, and micro inflammation 16, 17) . VC is a key feature of advanced atherosclerosis and the extent of calcification is strongly correlated with the extent and severity of atherosclerotic lesions 18) . Previous studies have shown that atherosclerotic risk factors, such as hypertension (HT), dyslipidemia (DL), and diabetes mellitus (DM), affect the prevalence and progression of VC 5, 8, 9, [19] [20] [21] . These factors affect renal functional deterioration and atrophy as well [22] [23] [24] . Although both VC progression and renal functional/morphological changes are influenced by atherosclerosis, the relationship between VC and renal dynamics in patients with CKD remains unknown.
Aim
VC can be evaluated semi-quantitatively in coronary and abdominal arteries as the coronary artery calcification (CAC) score (CACS) and abdominal aortic calcification index (ACI), respectively. Therefore, this study aims to investigate the relationship between renal functional/morphological parameters and progression of CACS or ACI in patients with CKD without hemodialysis.
Methods

Patients
From September 2009 to January 2013, 261 asymptomatic, pre-dialysis patients with CKD were recruited to undergo non-contrast coronary and abdominal computed tomography (CT) scans simultaneously in the outpatient clinic at the Department of Nephrology in the Nagoya University Hospital. CKD was defined as an estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m 2 or the presence of proteinuria and/or renal disease at study entry 25) . Among these patients, 79 underwent followup non-contrast coronary and abdominal CT scans by August 2016 over a 1-year interval. Among the 79 patients, no patient had a history of coronary artery disease, abdominal aortic artery repair and stenting, active malignancy, and/or active autoimmune disease. After excluding patients with polycystic kidney disease (n 2), hemodialysis maintenance between follow-up periods (n 1), unclear CT images (n 1), and coronary intervention during the follow-up periods (n 5), we evaluated 70 patients in this study. Coronary CT scans were used to determine CACS in Agatston units (AU), and abdominal CT scans were used to determine ACI as the abdominal artery calcification (AAC) score and renal parenchymal volume (RPV). In addition, all patients underwent renal functional tests and comprehensive atherosclerotic screening. When we evaluated the progression of VC, we calculated the annualized variation (calculated as [second value − first value/days of follow-up] 365) to determine the relationship between the annualized CACS variation ( CACS/y) or annualized ACI variation ( ACI/y) and baseline variables or annualized variations with regard to renal function and morphology. The study protocol was approved by the Ethics Review Board of Nagoya University School of Medicine, and written informed consent was obtained from all patients prior to performing the first CT scan.
HT was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, and/or the present use of anti-hypertensive medications. DL was defined as low-density lipoprotein (LDL) cholesterol ≥ 140 mg/dL, high-density lipoprotein (HDL) cholesterol 40 mg/dl, triglycerides ≥ 150 mg/dL, and/or the present use of anti-hyperlipidemic medications. DM was defined as fasting plasma glucose concentration 126 mg/dL, glycosylated hemoglobin concentration ≥ 6.5% (National Glycohemoglobin Standardization Program), and/or the present use of anti-hyperglycemic medications. Those who reported as presently smoking or previously smoked at least one cigarette per day for more than 1 year were defined as patients with a history of smoking.
CKD stages were classified using eGFR and urinary protein excretion data. To estimate GFR, we used a modified equation for Japanese: eGFR (mL/ min/1.73 m 2 ) 194 serum creatinine 1.094 age 0.287 0.739 (in females) 26) . Urinary protein excretion was determined via the urinary protein to creatinine ratio (PCR) in spot morning urine samples. We categorized eGFR levels into the following six groups according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Guidelines 25) : ≥ 90, 60-89, 45-59, 30-44, 15-29, and 15 mL/ min/1.73 m 2 , which were G1, G2, G3a, G3b, G4, and G5, respectively. We divided patients into the following three groups with regard to the urinary PCR: 0.15, 0.15-0.49, and ≥ 0.5 g/gCr, which were A1, A2, and A3, respectively.
CACS Measurements
All patients underwent CACS measurements using a multi-slice non-contrast CT scan (Siemens Medical Solutions, Forchheim, Germany) with a gantry rotation of 0.4 s, collimation of 2.5 mm (slice thickness), and reconstruction time of 6 frames/s. The images were scored by a single physician blinded to the clinical and biochemical aspects of the study patients. CACS was determined by multiplying the area of each calcified lesion by a weighting factor corresponding to the peak pixel intensity for each lesion and then summing the calcification scores of all coronary arteries 27, 28) . Lesions above a threshold of 130 Hounsfield units (HU) were defined as calcified.
ACI Measurements
ACI and RPV measurements for each patient were obtained in a manner similar to that for CACS measurements; that is, using multi-slice non-contrast CT scans. It is noteworthy that images were obtained with a 5-mm slice thickness. Calcification was considered to be present if an area of ≥ 1 mm 2 displayed a density of 130 HU. The AAC score was calculated from the site where the renal artery arises to the bifurcation into the common iliac arteries of the aorta. The cross-section of the abdominal aorta on each slice was radially divided into 12 segments. ACI was calculated as follows: ACI (total calcification score on all slices)/12 1/(number of slices) 100% 6, 10, 15) . ACI was independently calculated by two physicians who were blinded to the clinical and biochemical aspects of each study patient.
RPV Measurements
RPV was calculated based on a software that measures volume, which is available on Ziostation2 (Zio Software Inc., Tokyo, Japan). This is a threedimensional (3D) volumetric method that is widely used to measure renal volume 29, 30) . The renal cortex was traced on each image showing the renal parenchyma, with the exclusion of sinus fat, vessels, and cysts. After complete tracing of each kidney, CT volume was automatically calculated and RPV was defined as the sum of renal volume on the left and right sides (Fig. 1) . RPV measurement was conducted independently by two physicians who were blinded to the clinical and biochemical aspects of each study patient. Previous study showed that RPV can be corrected via the body surface area (BSA) (correction value 0.68) 30) ; we applied this correction by dividing RPV with BSA and defined it as the RPV index (RPVI), which was used in downstream analyses.
Statistical Analysis
All variables were expressed as means standard deviations or as medians and interquartile ranges for non-parametric variables. Categorical data were expressed as a number (percentage). Between-group differences were tested using the Student's t-test for parametric variables and the Mann-Whitney U-test for non-parametric variables. Categorical variables were examined using the Pearson chi-squared test or Fisher's exact test as appropriate. When the associations between CACS/y or ACI/y and various parameters were evaluated, baseline variables and annualized variations were independently calculated using correlation coefficients and a linear regression analysis. To reveal the independent factors associated with the progression of VC, significant variables identified by univariate analysis were entered in multivariable linear regression models. A significant difference is assumed with p 0.05 for all analyses. All statistical analyses were performed using JMP statistical software version 11.0.0 (SAS Institute Inc., Cary, NC, USA).
Results
Patient Characteristics and Variable Parameter Changes
A total of 70 patients were evaluated in this study. The median duration between the first and repeated CT scans was 4.6 (3.2-5.4) years. The baseline clinical characteristics and changes of CACS, RPVI, and laboratory data are summarized in Table 1 . The etiology of kidney disease was as follows: Nephrosclerosis in 32 patients (45.7%), glomerulonephritis in 20 patients (28.6%), diabetic nephropathy in 7 patients (10.0%), interstitial nephritis in 1 patient (1.4%), and other diseases and unknown in 10 patients (14.3%). The percentage of medication usage did not statistically increase during the study, with the exception of phosphate binders (from 5.7% at baseline to 17.1% at follow-up, p 0.034).
CACS (in AU) and ACI significantly increased from 40 Fig. 1) . The baseline values of CACS, ACI, and RPVI in each CKD stages are summarized in Table 2 . Although patients with CKD A3 exhibited a trend of higher CACS, there were no statistical differences between both CKD G and A stages at the baseline CACS or ACI. On the other hand, as the CKD G stage worsened, RPVI significantly decreased (p 0.001).
CACS/y or ACI/y profiles in patients with CKD
The comparisons of CACS/y and ACI/y with clinical characteristics are presented in Fig. 2 . Progressive CAC was significantly associated with risk factors, such as HT, DL, DM, and CKD stage A3 (Fig. 2-A) , and progressive ACI was associated with HT ( Fig.  2-B) . At baseline, CACS, RPVI, serum albumin, alkaline phosphatase, glycated hemoglobin (HbA1c), and urinary PCR for CACS/y and ACI, serum albumin, calcium, brain natriuretic peptide (BNP), and hemoglobin for ACI/y were significantly related variables (Supplemental Table 1 ). Multivariable linear regression analysis revealed that DM status ( 0.161, p 0.037) and CACS at baseline ( 0.735, p 0.001) for CACS/y and HT status ( 0.238, p 0.046) and ACI at baseline ( 0.285, p 0.017) for ACI/y were significantly independent predictors (Table 3-A) . In the annualized variation, there was a positive correlation between CACS/y and ACI/y (R 0.351, p 0.003) (Fig. 3-A) . CACS/y significantly correlated with the annualized variations of BSA ( BSA/y) (R 0.249, p 0.038) and RPVI ( RPVI/y) (R 0.565, p 0.001) (Supplemental Table 2 , Fig. 3-B) . Moreover, multiple linear regression analysis revealed that RPVI/y ( 0.537, p 0.001) was an independent factor for CACS/y (Table 3-B) . A similar trend was observed in the analysis for ACI/y. Although many annualized variations, such as body weight (BW), RPVI, eGFR, calcium, intact parathyroid hormone, BNP, and HbA1c were corrected with ACI/y (Supplemental Table 2 , Fig. 3-C) , multiple linear regression analysis revealed that BW/y ( 0.446, p 0.001), RPVI/y ( 0.371, p 0.015), and HbA1c/y ( 0.264, p 0.041) were independent factors for ACI/y (Table 3-B) . On the other hand, eGFR at baseline and annualized eGFR variation ( eGFR/y) did not significantly correlate with CACS/y and ACI/y in the multivariable analysis.
Discussion
There is a high prevalence of rapid VC progression in patients with CKD [7] [8] [9] [10] , which is prognostically related to the increased morbidity and mortality of CVD [11] [12] [13] [14] [15] . In this study, we discerned the relationship between CAC or AAC progression and renal functional/morphological changes and revealed the following results: 1) CACS at baseline and DM were independent predictors for CAC progression.
2) ACI at baseline and HT were independent predictors for AAC progression.
3) In annualized variations, a decrease in RPV, but not in eGFR, were significantly related to both CAC and AAC progression.
To our knowledge, this is the first study dissecting and clarifying the intimate relationships between RPV and VC progression.
Several studies have reported that the presence of calcification, DM, and HT are strong indicators for progressive calcification, while VC absence in patients with CKD strongly implies a lack of calcification during disease progression 8, 9, 13) . Stavroulopoulos et al. 9) have reported that patients with CKD with DM have a higher prevalence and greater increase in CACS than patients with CKD with non-DM. Hyperglycemia and insulin resistance lead to osteogenic differentiation of vascular smooth muscle cells 31) , and an accumulation of advanced glycation end products resulting from long-term hyperglycemia have been reported to be associated with CAC 32) . HT is a well-established risk factor for arterial stiffness and medial calcification 33) , and some previous studies have revealed that pulse blood pressure levels promote AAC progression 10, 34) . VC occurs in the intima in association with atherosclerosis, which is characterized by an increase in the deposition of plaques, and in the media in association with arteriosclerosis, which is characterized by vascular stiffening due to loss of elasticity of the arterial musculature 33, 35) . A previous study has revealed that there is a significant relationship between CAC and AAC 36) , and our study revealed that both the annualized variations had a significant correlation in the same manner (Fig. 3-A) . Although a combination of intimal and medial calcification may occur in patients with CKD, CAC is considered to be mainly due to intimal calcification and AAC to be due to medial calcification. This is why there is a difference in the predict factors between CAC and AAC progression.
Interestingly, we found that renal morphological change was associated more strongly with VC variability over time than eGFR in our patient cohort despite there being a correlation between RPVI and eGFR. This means that the more advanced renal atrophy becomes, the more severe VC is formed. Although GFR is an indicator of the filtration ability of kidneys and eGFR is an excellent marker that can be estimated based on serum creatinine levels, serum creatinine is affected by muscle mass and nutritional status. In addition, serum creatinine levels may be underestimated in the elderly 37) . On the other hand, RPV, excluding tissues that do not contribute to renal function, can be quantitatively and accurately measured based on CT images and more reflective of renal function, including renal endocrine and tubular function in addition to filtration ability. Renal atrophy results from global glomerulosclerosis, tubular atrophy, and interstitial fibrosis due to macro-and microvascular damage 22) . -Klotho is one of the most important regulating factors influenced by vascular calcification and facilitates normal phosphaturic function of FGF23 in the kidneys 38, 39) . -Klotho is expressed mostly in renal tubular cells and parathyroid glands, and production and serum levels decline upon decreased renal function 40, 41) . In addition, the serum level of 1,25-dihydroxyvitamin D3, which is involved in calcium regulation, decreases as renal function declines 40) . Moreover, tubular atrophy downregulates the expression of various proteins associated with vascular calcification. Thus, changes in RPV, but renal function estimated by eGFR, may strongly synchronize with VC progression.
The decrease of BW was another independent associated factor for ACI/y in our study. This is considered to occur because of malnutrition in patients with CKD. Recent data have suggested that malnutrition can trigger CKD-mineral bone disorder and accelerate VC progression 42) . Previous studies have revealed that phosphate overload leads to mineral bone abnormalities and directly promotes systemic malnutrition and VC in CKD 43, 44) , and this is one of the reasons why lowering the phosphate level is effective in reducing calcification. In our study, HbA1c changes are also negatively associated with ACI/y. This mechanism is not clear; however, because HbA1c improves according to the deterioration of renal function and malnutrition, these changes are considered to have secondarily affected ACI/y. There are several limitations to our study. First, this study was conducted in a single center and included few patients. Second, 7 patients with diabetic nephropathy were enrolled in our study. Although, in some cases, renal volume is expanded in the early phase of diabetic nephropathy, there was no impact on the relationship between CACS/y or ACI/y and RPVI/y when we eliminated these patients from our study. Furthermore, the prevalence of diabetic nephropathy in this study was much less than that in the general patient population. There are two possible reasons for this. The first reason is that this study was conducted at a single university hospital and had an etiologic bias. The second reason is that some patients with diabetic nephropathy were excluded because they had undergone coronary intervention in the past. At last, when we performed the measurement of renal volume by CT scan, radiation exposure was increased in comparison with non-invasive sonography. However, we adopted this method because estimating CTbased renal parenchymal volume was more accurate than sonographic measurement.
Conclusion
VC progression was strongly associated with changes in renal volume and predicted by a high baseline VC as well as the presence of atherosclerotic diseases, such as DM and HT, in patients with CKD who were not on dialysis. With regard to VC progression, changes in renal volume provided more information than conventional indicators of kidney function, such as eGFR and urinary protein. When treating patients with CKD, clinicians should bear in mind that baseline VC presence, DM, HT, and renal volumes are crucial factors that may enhance VC progression and thus cardiovascular disease. 
